奈拉滨联合方案治疗复发或难治性T细胞急性淋巴细胞白血病/淋巴瘤
该回顾性研究分析了44例复发或难治性T细胞急性淋巴细胞白血病/淋巴瘤患者,其中29例接受联合治疗(多数为环磷酰胺联合依托泊苷),15例接受单药治疗。联合治疗组24个月总生存率53% vs 单药组8%(P = .003),神经毒性相似,但3/4级贫血和血小板减少更常见。多因素分析显示联合治疗和后续异基因造血干细胞移植与总生存改善相关。
要点
- 联合治疗组完全缓解率62%(18/29)vs 单药组40%(6/15),差异无统计学显著(P = .21)。
- 联合治疗组24个月总生存率53% vs 单药组8%(P = .003)。
- 联合治疗组3/4级贫血76% vs 单药组20%(P < .001),血小板减少66% vs 27%(P = .014)。
核心结论
- 与单药治疗相比,奈拉滨联合治疗耐受性良好,并与复发或难治性T细胞急性淋巴细胞白血病/淋巴瘤儿童和成人患者的总生存改善相关。
研究设计与样本
- 回顾性分析44例连续纳入的复发或难治性T细胞急性淋巴细胞白血病/淋巴瘤患者,其中29例接受联合治疗(23例,79%,为环磷酰胺联合依托泊苷),15例接受单药治疗;中位年龄19岁(范围2-69岁),包括18例儿童(<18岁);中位治疗1个周期(范围1-3)。
主要发现
- 24例患者(55%)达到完全缓解,联合治疗组62%(18/29)vs 单药组40%(6/15)(P = .21)。
- 大多数缓解者(21例,88%)后续接受异基因造血干细胞移植。
- 整个队列总生存期为12.8个月(95%置信区间,6.93-未达到),联合治疗组高于单药组(24个月总生存率,53% vs 8%;P = .003)。
- 神经毒性发生率两组相似(27% vs 17%;P = .46)。
- 3/4级贫血和血小板减少在联合治疗组更常见(贫血76% vs 20%;P < .001;血小板减少66% vs 27%;P = .014)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nelarabine, an antimetabolite prodrug, is approved as monotherapy for children and adults with relapsed and refractory T-cell acute lymphoblastic leukemia and lymphoma (R/R T-ALL/LBL), although it is often used in combination regimens. We sought to understand differences in efficacy and toxicity when nelarabine is administered alone or in combination. We retrospectively analyzed 44 consecutive patients with R/R T-ALL/LBL; 29 of whom were treated with combination therapy, most with cyclophosphamide and etoposide (23, 79%) and 15 with monotherapy. The median age was 19 years (range, 2-69), including 18 children (<18 years). After a median of 1 (range, 1-3) cycle of treatment, 24 patients (55%) achieved complete remission, 62% (18/29) with combination therapy and 40% (6/15) with monotherapy (P = .21). Most responders (21, 88%) pursued allogeneic stem cell transplant (alloSCT). Overall survival (OS) was 12.8 months (95% confidence interval, 6.93-not reached) in the entire cohort and was higher in the combination therapy than in the monotherapy group (24-month OS, 53% vs 8%; P = .003). The rate of neurotoxicity was similar between groups (27% vs 17%; P = .46) and grade 3/4 anemia and thrombocytopenia were more frequent in the combination group (76% vs 20%; P < .001% and 66% vs 27%; P = .014, respectively). In a multivariate analysis, nelarabine combination therapy and alloSCT post nelarabine were associated with improved OS (hazard ratio, 0.41; P = .04 and hazard ratio, 0.25; P = .008, respectively). In conclusion, compared with monotherapy, nelarabine combination therapy was well tolerated and associated with improved survival in pediatric and adult patients with R/R T-ALL/LBL.
引用
- Shimony S, Liu Y, Valtis YK, et al. Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia. Blood Adv. 2023. PMID: 36508268. doi:10.1182/bloodadvances.2022008280
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。